BioVie Inc. (NASDAQ:BIVI) experienced a significant increase in call options trading activity on Friday, with investors purchasing 12,329 call options on the company, marking a 1,033% increase compared to previous trading activity. The stock traded up $0.59 on Friday, reaching $1.83. BioVie has a market capitalization of $72.96 million and a beta of 0.84. The company's stock has a twelve-month low of $0.89 and a twelve-month high of $11.39. Several large investors have recently made changes to their holdings of BIVI. BioVie is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States [44747ddd].
Navitas Semiconductor Co. (NASDAQ:NVTS) also experienced unusually high options trading activity on Friday, with traders buying 12,102 call options on the stock, an increase of approximately 679% compared to the typical daily volume. The stock is currently trading at $5.64, down 8.1% from the previous close. In the last 90 days, insiders have sold 127,060 shares of company stock valued at $991,592. Institutional investors own 37.45% of the stock [05c408e1].
Blueprint Medicines Corporation has announced that it has granted non-qualified stock options and restricted stock units (RSUs) to three new employees under its 2020 Inducement Plan. The options have an exercise price of $96.42 per share and will vest over time, subject to each employee's continued employment. The RSUs will also vest over time. The grants were made under Nasdaq Listing Rule 5635(c)(4). Blueprint Medicines is a global biopharmaceutical company focused on allergy/inflammation and oncology/hematology [8aeff54e].
The State of Tennessee Treasury Department has increased its stock holdings in Biogen Inc. (NASDAQ:BIIB) by 71.1% during the 4th quarter, acquiring an additional 26,350 shares. The department now owns 63,396 shares of Biogen, worth $16,405,000. Other institutional investors have also recently bought and sold shares of the company. Biogen's stock is currently trading at $225.74 on NASDAQ. The company has a market capitalization of $32.87 billion, a P/E ratio of 28.18, and a beta of -0.02. Biogen reported $3.67 EPS for the last quarter, beating analysts' consensus estimates of $3.45. The company had revenue of $2.29 billion for the quarter. Ten investment analysts have rated the stock as a hold, while seventeen have issued a buy rating. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide.